Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstracts Accepted at AACR-NCI-EORTC 2021

On September 30, 2021 Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported that five abstracts have been selected for presentation as virtual posters at the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) on October 7 – 10, 2021 (Press release, Tango Therapeutics, SEP 30, 2021, View Source [SID1234590595]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The preclinical data being presented today highlight the potential applicability of synthetic lethal drug targeting across a range of cancer types. As an example, our lead program, TNG908, an MTA-cooperative PRMT5 inhibitor selective for cancers with deletion of the MTAP gene, shows strong regressions across multiple types of cancer," said Barbara Weber, M.D., president and Chief Executive Officer of Tango Therapeutics. "We look forward to leveraging these data to inform our planned clinical development program."

Dr. Weber will also be co-chairing an Educational session titled "Exploiting Synthetic Lethality" on October 7, 2021 at 10:00 AM ET.

Details on Tango’s presentations at AACR (Free AACR Whitepaper)-NCI-EORTC are as follows:

Poster Title: MTAPnull-selective PRMT5 inhibitors drive regressions in MTAP-deleted xenograft models across histologies
Abstract #: P214
Date and Time: October 7, 9:00 AM ET

Poster Title: VRK1 is a novel synthetic lethal target in VRK2-methylated glioblastoma
Abstract #: P182
Date and Time: October 7, 9:00 AM ET

Poster Title: CRISPR screens identify sensitizers to Trametinib in KRAS mutant cancer cell lines
Abstract #: P183
Date and Time: October 7, 9:00 AM ET

Poster Title: Loss of HS2ST1 cooperates with MAPK inhibition to impair growth of mesenchymal KRAS mutant NSCLC
Abstract #: P146
Date and Time: October 7, 9:00 AM ET

Poster Title: Isogenic CRISPR Anchor Screens identified actionable nodes to CHK1/2 inhibitor Prexasertib in TP53 mutant cancer
Abstract #: P095
Date and Time: October 7, 9:00 AM ET

CatalYm To Present Update From GDF-15 Targeting First-in-Human I/O Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

On September 30, 2021 CatalYm reported that a data update from their ongoing first-in-human trial "GDFather" (GDF-15 Antibody-mediated Effector cell Relocation) has been accepted for oral presentation at the 2021 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) (Press release, Catalym, SEP 30, 2021, View Source [SID1234590594]). The conference will be held virtually from October 7 -10, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"GDF-15 is frequently overexpressed in various tumor types and appears to play a central role in suppressing several key mechanisms by which the immune system recognizes and eliminates tumors, making it an exciting target in immuno-oncology drug development. We look forward to presenting an update from this trial to the scientific community in an oral plenary session," said Eugen Leo, MD, PhD, MBA, Chief Medical Officer at CatalYm.

Details of the oral presentation:

Presentation title: A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors

Session title: New Drugs on the Horizon II

Speaker: Eugen Leo, MD, PhD, MBA, Chief Medical Officer of CatalYm

Date/time: October 9, 2021, at 4.05 pm ET/22.05 pm CEST

About the GDFather Trial

The ongoing first-in-human GDFather trial (GDF-15 Antibody-mediaTed Effector cell Relocation) is a two-part, open-label study to evaluate GDF-15 inhibitor CTL002 in advanced, checkpoint inhibitor refractory or relapsed solid tumor patients. In the dose escalation phase (Part A), up to 24 patients will receive escalating doses of CTL-002 in a "3+3" manner with the lead candidate given as a monotherapy and followed by combination with an anti-PD-1 checkpoint inhibitor. In the second dose expansion phase (Part B, phase 2a), several cohorts with tumors identified to be GDF-15-dependent will be treated to further evaluate safety and preliminary efficacy of CTL-002 treatment.

About CTL-002

CTL-002 is a humanized, monoclonal antibody designed to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15). GDF-15 secretion by the tumor has been shown to prevent T cell migration into the tumor and suppresses T cell function and the adaptive immune response in the tumor microenvironment. All these mechanisms help the tumor evade the immune system and become resistant to standard of care and current immunotherapy approaches such as checkpoint inhibitors. CTL-002 counteracts these immuno-suppressive mechanisms by neutralizing GDF-15, enhancing the infiltration of immune cells into the tumor, improving both priming of T cells by dendritic cells and tumor killing by T cells and NK cells.

Repare Therapeutics to Present Initial Data from the Phase 1/2 TRESR RP-3500 Clinical Trial at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

On September 30, 2021 Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, reported that it has been selected for an oral presentation of initial monotherapy clinical data from its ongoing Phase 1/2 clinical trial of RP-3500 and a poster presentation of preclinical data for RP-3500 at the upcoming AACR (Free AACR Whitepaper)-NCI-EORTC Virtual AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), being held October 7-10, 2021 (Press release, Repare Therapeutics, SEP 30, 2021, View Source [SID1234590593]). In addition, the Company will be hosting a Virtual Investor Webcast Event on Friday, October 8, 2021 at 5:00 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation Details on RP-3500 Early TRESR Monotherapy Trial Results:
Title: First-in-Human biomarker-driven phase I TRESR trial of ataxia telangiectasia and Rad3-related inhibitor (ATRi) RP-3500 in patients (pts) with advanced solid tumors harboring synthetic lethal (SL) genomic alterations
Presenter: Dr. Timothy Yap, MBBS, Ph.D., FRCP, Medical Director, Institute for Applied Cancer Science, Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas
Abstract Number: 4950
Session Title: Concurrent Session 04: Novel Precision Medicine Combination Trials
Date/Time: Friday, October 8, 2021 at 3:15 p.m. ET

Poster Presentation Details on Preclinical data for RP-3500 Alone and in Combination with PARP Inhibitors:
Title: RP-3500: A Novel, Potent and Selective ATR Inhibitor that is Effective in Pre-Clinical Models as a Monotherapy and in Combination with PARP Inhibitors
Presenter: Anne Roulston, Ph.D., Repare Therapeutics
Poster Number: P054
Date/Time: Thursday, October 7, 2021, at 9:00 a.m. ET

Company Virtual Investor Webcast Event Details:

The Company will host a virtual investor webcast on Friday, October 8, 2021 at 5:00 p.m. ET to further discuss the initial monotherapy RP-3500 data that will be presented at the AACR (Free AACR Whitepaper)-NCI-EORTC Virtual AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper). Repare’s executive management team will be joined by Dr. Timothy Yap, MBBS, Ph.D., FRCP, MD Anderson Cancer Center, Houston, Texas.

A live video webcast and presentation slides will be available on the Investor section of the Company’s website at View Source A webcast replay will also be available for at least 30 days following the call.

About RP-3500

RP-3500 is a potent and selective oral small molecule inhibitor of ATR (Ataxia Telangiectasia and Rad3 related protein kinase) being developed for the treatment of solid tumors with specific genome instability related genomic alterations including those in the ATM (ataxia-telangiectasia mutated) gene.

About Repare Therapeutics’ SNIPRx Platform

Repare’s SNIPRx platform is a genome-wide CRISPR-based screening approach that utilizes proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and the corresponding patients who are most likely to benefit from the Company’s therapies based on the genetic profile of their tumors. Repare’s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx screening, in order to selectively target those tumors in patients most likely to achieve clinical benefit from resulting product candidates.

Bicycle Therapeutics to Present BT5528 Interim Phase I Data at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

On September 30, 2021 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported that interim Phase I results from its Phase I/II trial of BT5528, a second-generation Bicycle Toxin Conjugate (BTC) targeting EphA2, has been selected for a plenary oral presentation at the upcoming AACR (Free AACR Whitepaper)-NCI-EORTC Virtual AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), being held October 7-10, 2021 (Press release, Bicycle Therapeutics, SEP 30, 2021, View Source [SID1234590592]). The Company will host a conference call to discuss the results and provide an update on preliminary findings from the BT8009 program on Thursday, October 7, 2021 at 3:00 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AACR-NCI-EORTC Plenary Oral Presentation Details:
Title: A first in class phase I/II Study of the Novel Bicyclic Peptide and MMAE Conjugate, BT5528, in patients with Advanced Malignancies Associated with EphA2 Expression
Presenter: Meredith McKean, M.D., Sarah Cannon Research Institute at Tennessee Oncology
Session Title: Tumor-targeted Conjugates: A Growing Family
Date/Time: Thursday, October 7 at 12:50 p.m. ET

Conference Call Details
Bicycle Therapeutics will host a conference call and webcast on Thursday, October 7 at 3:00 p.m. ET to review the data being presented and provide an update on preliminary findings from the BT8009 program. To access the call, please dial (800) 377-9118 (domestic) or (409) 937-8920 (international) and provide the Conference ID 2287246. A live webcast of the presentation will be available on the Investors & Media section of the Bicycle website, bicycletherapeutics.com.

Susan G. Komen®: Year of Screening Delays and Treatment Disruptions Due to COVID-19 Threaten Breast Cancer Progress

On September 30, 2021 Susan G. Komen, the world’s leading breast cancer organization, reported that it is warning that decades of progress in lowering breast cancer mortality rates may be in jeopardy due to the ongoing COVID-19 pandemic and called for a united response to help save lives during this year’s National Breast Cancer Awareness month (Press release, Susan G Komen, SEP 30, 2021, View Source [SID1234590591]). Komen noted that in response to the growing need for financial support and overcoming barriers to care, the organization has increased its focus on providing care and support directly through its Patient Care Services Center, the demand for which has more than doubled over the past year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Facing a breast cancer diagnosis is difficult in the best of times, but more so during the uncertainty of a pandemic," said Paula Schneider, a breast cancer survivor and Komen’s CEO. "More people than ever are encountering challenges in accessing and continuing needed care. Many have lost their jobs, health insurance and are facing new financial challenges. The pandemic has also highlighted persistent and tragic racial disparities, like the startling reality that Black women in the U.S. are about 40 percent more likely to die from breast cancer than white women. Our support is needed now, more than ever. Yet meeting those needs will only be possible thanks to the generosity and passion of our donors and fundraisers."

Komen noted that there are many ways that people can help support Komen’s advocacy, research and patient care programs, from fundraising through one of the organization’s local Race for the Cure or MORE THAN PINK Walk events, supporting someone walking in the Komen 3-Day, 60 mile walk, supporting one of Komen’s LIVE Pink partners, or by doing a personal fundraiser that is meaningful to you, such as hosting a Dress Up to Take Down Breast Cancer educational session or fundraiser at work.

The need for support is clear and growing more urgent by the day. Komen noted that while progress has been made in lowering mortality rates from breast cancer by 41 percent in the U.S. since 1989 thanks to more than three decades of increased access to early detection and more effective treatments, the trajectory of that progress is now in jeopardy due to COVID-19’s lingering impact on breast health care.

Without a renewed focus on early detection and efforts to maintain people in the continuum of care, as well as investments in improved treatments, we are likely to see more people die from the disease. Even without taking the impact of COVID-19 on screening and treatment into account, more than 44,000 people are expected to die this year from breast cancer in the U.S. alone. Now, due to the pandemic, which has caused people to become hesitant to get screened or see a doctor, suddenly become uninsured or face new financial challenges, people are facing new delays and barriers to care that are likely to have tragic consequences.

Initial reports from the National Cancer Institute in 2020 suggested there could be an excess of 10,000 deaths due to breast and colorectal cancer by 2030 due to the pandemic.
A newer model in July 2021, suggests about 2,500 excess deaths from breast cancer by 2030 are expected to occur due to reduced screening, delays in diagnosis and decreased chemotherapy use among women with estrogen receptor positive early breast cancer.
While screening rates are rebounding from the pandemic lows, we are still catching up for many people who should have already been screened and diagnosed. This may lead to a surge of new breast cancers, with later stage diagnoses and increased mortality.
While healthcare systems were able to adapt and adjust treatment regimens to better support patients during this challenging time, many people experienced a change or delay in treatment in the midst of the pandemic.
In response to the growing and evolving demand for direct support for those facing breast cancer today, Komen has developed a new national Patient Care Center to help people overcome barriers to care, no matter where they live. These services include a free Breast Care Helpline, where callers are connected to a trained oncology social worker who provides emotional support education, and access to resources such as financial assistance, patient navigation and more. The need for these care services continues to grow. For example, this year:

Demand for Komen’s free Breast Care Helpline has increased by 35 percent year-over-year.
Komen’s Treatment Assistance Program has provided financial support for thousands of patients and has seen a 155% increase in the number of patients served compared to last year.
Komen recently added eight patient navigators to its team to connect patients to support and resources that will help keep them in the continuum of care. The organization plans to add nine more navigators by the spring of 2022 to meet the growing need.
"In a single moment, a person’s life changes forever – there is life before breast cancer, and life after," noted Schneider. "This October, as part of National Breast Cancer Awareness Month, we are asking people to take a moment to make a difference in the lives of their neighbors. One action can help save a life."